Hypoglossal Nerve Stimulation (HGNS)
Treatment for Sleep Apnea
Typical Dosage: Device programmed settings
Effectiveness
80%
Safety Score
65%
Clinical Trials
14
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Device programmed settings
Time to Effect
2-3 months
Treatment Duration
Lifetime (with battery replacements)
Evidence Quality
MODERATENumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$4,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$6,923
Cost per Remission
$10,000
Active Clinical Trials
10 active trials recruiting for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea
Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation
NCT06317701RECRUITING
30 participants
OBSERVATIONAL
Chicago, United States
Started: Apr 4, 2024
Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
NCT06720545RECRUITINGNA
60 participants
INTERVENTIONAL
New York, United States
Started: Jan 5, 2025
Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse
NCT07724938RECRUITINGNA
72 participants
INTERVENTIONAL
Boston, United States
Started: Sep 15, 2026
Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea
NCT07049744RECRUITINGNA
30 participants
INTERVENTIONAL
Canberra, Australia +5 more
Started: Jun 24, 2025
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea
NCT07577661RECRUITINGPHASE1, PHASE2
24 participants
INTERVENTIONAL
Boston, United States
Started: Sep 1, 2026
Obstructive Sleep Apnea Non-PAP Outcomes and Viable Alternatives
NCT07074288RECRUITINGNA
60 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 30, 2025
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
NCT07220525RECRUITINGNA
100 participants
INTERVENTIONAL
San Francisco, United States
Started: Dec 15, 2025
Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through Mandibular Advancement
NCT07132307RECRUITINGNA
30 participants
INTERVENTIONAL
St Louis, United States
Started: Jul 29, 2025
An Extension Study to Assess the Long-term Safety of the Genio® System
NCT05939141NOT YET RECRUITING
39 participants
OBSERVATIONAL
Sydney, Australia +6 more
Started: Nov 1, 2025
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002ACTIVE NOT RECRUITINGNA
124 participants
INTERVENTIONAL
Colorado Springs, United States +15 more
Started: Dec 28, 2022
Completed Clinical Trials
4 completed trials for Hypoglossal Nerve Stimulation (HGNS) in Sleep Apnea
Hypoglossal Nerve Stimulation on Cardiovascular Outcomes
NCT03359096COMPLETEDNA
63 participants
INTERVENTIONAL
Philadelphia, United States
Started: Dec 13, 2017
Mechanisms of Upper Airway Obstruction
NCT04322097COMPLETEDNA
133 participants
INTERVENTIONAL
Philadelphia, United States
Started: Jun 3, 2020
US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea
NCT01211444COMPLETEDPHASE2, PHASE3
20 participants
INTERVENTIONAL
San Francisco, United States +3 more
Started: Jul 1, 2010
Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea
NCT01186926COMPLETEDPHASE2, PHASE3
40 participants
INTERVENTIONAL
Started: Mar 1, 2009